Close Menu

NEW YORK (GenomeWeb) – Transgenomic today priced its public offering of stock and warrants, expecting to raise $6.2 million in net proceeds. 

The firm is offering 3,573,899 shares of its common stock, as well as corresponding warrants to purchase 714,780 shares of its stock. The stocks and warrants will be sold in combination with one warrant to purchase .20 of a share of stock for each share of stock sold. The combined price for each share and corresponding warrant is $1.95, Transgenomic said. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.